Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?

Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis

(2015) Johanna H. M. Driessen et al.   CALCIFIED TISSUE INTERNATIONAL

Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture

(2014) Johanna H.M. Driessen et al.   BONE

Osteoporosis, Fractures, and Diabetes

(2014) Peter Jackuliak et al.   International Journal of Endocrinology

Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Prevents Osteopenia by Promoting Bone Formation and Suppressing Bone Resorption in Aged Ovariectomized Rats

(2013) Xue Ma et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials

(2013) Ann V Schwartz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor

(2013) Guillaume Mabilleau et al.   JOURNAL OF ENDOCRINOLOGY

Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS

(2013) L van Bloemendaal et al.   JOURNAL OF ENDOCRINOLOGY

Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes

(2013) Ju-Young Kim et al.   LIFE SCIENCES

Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials (胰高血糖素样肽-1受体激动剂的使用与骨折的关系：一项对随机临床试验的meta分析)

(2013) Guillaume Mabilleau et al.   Journal of Diabetes

Bone Metabolism in Obesity and Weight Loss

(2012) Sue A. Shapses et al.   Annual Review of Nutrition

Impact of Common Variation in Bone-Related Genes on Type 2 Diabetes and Related Traits

(2012) L. K. Billings et al.   DIABETES

Shear strength behavior of human trabecular bone

(2012) Arnav Sanyal et al.   JOURNAL OF BIOMECHANICS

Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus

(2012) Agostino Gaudio et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials

(2011) M. Monami et al.   DIABETES CARE

Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes

(2011) Ann V. Schwartz   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes

(2011) Borzo Gharibi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide

(2011) Laszlo Hegedüs et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland

(2011) Belinda Gier et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia

(2011) Bernardo Nuche-Berenguer et al.   JOURNAL OF ENDOCRINOLOGY

OPG/RANKL

(2011) Pierre Marie et al.   M S-MEDECINE SCIENCES

Sclerostin: Current Knowledge and Future Perspectives

(2010) M. J. C. Moester et al.   CALCIFIED TISSUE INTERNATIONAL

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

(2010) A. Papaioannou et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Insulin Signaling in Osteoblasts Integrates Bone Remodeling and Energy Metabolism

(2010) Mathieu Ferron et al.   CELL

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

(2010) Lotte Bjerre Knudsen et al.   ENDOCRINOLOGY

Effects of weight and body mass index on bone mineral density in men and women: The framingham study

(2010) David T. Felson et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor

(2010) Bernardo Nuche-Berenguer et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Structure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis

(2010) H. M. Ta et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

GIP and GLP-1, the two incretin hormones: Similarities and differences

(2010) Yutaka Seino et al.   Journal of Diabetes Investigation

Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow

(2009) C. Sanz et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States

(2009) Bernardo Nuche-Berenguer et al.   CALCIFIED TISSUE INTERNATIONAL

Is Wnt signalling the final common pathway leading to bone formation?

(2009) Frances Milat et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

WNT signalling is both an inducer and effector of glucagon-like peptide-1

(2008) B. Gustafson et al.   DIABETOLOGIA

Imbalance of RANK, RANKL and OPG expression during tibial fracture repair in diabetic rats

(2008) Fernanda Penna Lima Guedes de Amorim et al.   JOURNAL OF MOLECULAR HISTOLOGY

Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis

(2008) T. J. Martin et al.   OSTEOPOROSIS INTERNATIONAL

Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract

(2008) Ida B. Gottschalck et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Targeting the Wnt signaling pathway to augment bone formation

(2008) Mohammad Shahnazari et al.   Current Osteoporosis Reports

The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption

(2007) Chizumi Yamada et al.   ENDOCRINOLOGY